Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer InstituteAlternative Names: anti-KRAS-mutation; anti-SSX2 TCR; KITE-439; KITE-585; KITE-718; KRAS TCR; NEO Antigens; SSX2 TCR
Latest Information Update: 12 Jan 2017
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class Cell therapies; Gene therapies
- Mechanism of Action Antigen receptor antagonists; Cell replacements; Gene transference; T-cell receptor antigen antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer